Program
socazolimab
Also written as “ZKAB001 5mg/kg”, “ZKAB001 10mg/kg” and “ZKAB001 15mg/kg”.
Its studies are mostly in Uterine Cervical Neoplasms · Osteosarcoma · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Melanoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lee's Pharmaceutical | 81 open or running | phase 3since Apr 21, 2020 | Sep 12, 2018 | Sep 1, 2027phase 3 · NCT06459687 |
| Suzhou BlueHorse Therapeutics | 11 open or running | phase 2since Feb 26, 2026 | Feb 26, 2026 | Dec 31, 2027phase 2 · NCT07444437 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2018First study: phase 1 study in Uterine Cervical NeoplasmsNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03676959 · 101 enrolled · China
- Sep 13, 20182 phase 2 studiesLee's Pharmaceutical · NCT03676985, NCT03676946
- Apr 21, 2020Phase 3 study in High-grade OsteosarcomaLee's Pharmaceutical · NCT04359550 · 362 enrolled
- Oct 22, 2020Phase 1 study in Biliary Tract NeoplasmsLee's Pharmaceutical · NCT04608786 · 10 enrolled · China
- Apr 14, 2021Phase 2 study in Local Progression or Metastatic Melanoma With Failed First-line TreatmentLee's Pharmaceutical · NCT04849260 · 54 enrolled · China
- Apr 29, 2021Phase 3 study in Small Cell Lung CarcinomaLee's Pharmaceutical · NCT04878016 · 498 enrolled · China
- Jun 3, 2024Phase 3 study in Uterine Cervical NeoplasmsLee's Pharmaceutical · NCT06459687 · 440 planned · China
- Feb 26, 2026Suzhou BlueHorse Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Suzhou BlueHorse TherapeuticsSuzhou BlueHorse Therapeutics · NCT07444437 · 45 planned · China
Ahead
- Sep 1, 2027Primary completion: phase 3 study in Uterine Cervical NeoplasmsLee's Pharmaceutical · NCT06459687
- Dec 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungSuzhou BlueHorse Therapeutics · NCT07444437
TargetBeta
“A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07444437Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Suzhou BlueHorse Therapeutics | Dec 31, 2027 | 45 |
| NCT06459687Uterine Cervical Neoplasms · China | 3 | Recruiting | Lee's Pharmaceutical | Sep 1, 2027 | 440 |
| NCT04878016Small Cell Lung Carcinoma · China | 3 | Completed | Lee's Pharmaceutical | Oct 13, 2023 | 498 |
| NCT04849260Local Progression or Metastatic Melanoma With Failed First-line Treatment · China | 2 | UNKNOWN | Lee's Pharmaceutical | May 31, 2022 | 54 |
| NCT04608786Biliary Tract Neoplasms · China | 1 | UNKNOWN | Lee's Pharmaceutical | Dec 1, 2022 | 10 |
| NCT04359550High-grade Osteosarcoma | 3 | UNKNOWN | Lee's Pharmaceutical | Jun 1, 2022 | 362 |
| NCT03676985Osteosarcoma · China | 2 | UNKNOWN | Lee's Pharmaceutical | Feb 14, 2020 | 15 |
| NCT03676946Carcinoma, Transitional Cell · China | 2 | UNKNOWN | Lee's Pharmaceutical | Feb 14, 2020 | 15 |
| NCT03676959Uterine Cervical Neoplasms · China | 1 | UNKNOWN | Lee's Pharmaceutical | May 15, 2022 | 101 |
How it is read
Names in the registry
- “ZKAB001 5mg/kg”, 4 entries
- “ZKAB001 10mg/kg”, 3 entries
- “ZKAB001 15mg/kg”, 3 entries
- “PD-1 / PD-L1 monoclonal antibody”, 1 entry
- “Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 2 studies
- Osteosarcoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Small Cell Lung Carcinoma, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.